The PEERLESS Study (PEERLESS)

A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.

All-cause mortality, or Intracranial hemorrhage (ICH), or Major bleeding per ISTH definition, or Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapy, or ICU admission and ICU length-of-stay during the index hospitalization and following the index procedure.

All-cause mortality, or Intracranial hemorrhage (ICH), or Major bleeding per ISTH definition, or Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapy

Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapy

ICU admission and ICU length of stay during the index hospitalization and following the index procedure

Inclusion Criteria Subjects must meet each of the following criteria to be included in the study: Age ≥ 18 years Echo, computed tomographic pulmonary angiography (CTPA), or pulmonary angiographic evidence of any proximal filling defect in at least one main or lobar pulmonary artery Including ALL of the following: Clinical signs and symptoms consistent with acute PE, or PESI class III-V, or sPESI ≥1; AND Hemodynamically stable AND; RV dysfunction on echocardiography or CT; AND Any one or more of the following present at the time of diagnosis: Elevated cardiac troponin levels; History of heart failure; History of chronic lung disease; Heart rate ≥110 beats per minute; SBP <100mmHg; Respiratory rate ≥30 breaths per minute; O2 saturation <90%; Syncope related to PE; Elevated Lactate Intervention planned to begin within 72 hours of the later of either: confirmed PE diagnosis; OR if transferring from another hospital, arrival at the treating hospital Symptom onset within 14 days of confirmed PE diagnosis Exclusion Criteria Subjects will be excluded from the study for any of the following criteria: Unable to anticoagulate with heparin, enoxaparin or other parenteral antithrombin Index presentation with hemodynamic instability that are part of the high-risk PE definition in the ESC Guidelines 2019, including ANY of the following: cardiac arrest; OR systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥90 mmHg despite adequate filling status, AND end-organ hypoperfusion; OR systolic BP < 90 mmHg or systolic BP drop ≥40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g. inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot) Patient has right heart clot in transit identified at baseline screening Life expectancy < 30 days (e.g. stage 4 cancer or severe COVID-19 infection), as determined by the Investigator Current participation in another drug or device study that, in the Investigator's opinion, would interfere with participation in this study Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per ESC 2019 guidelines Invasive systolic PA pressure ≥70 mmHg prior to study device entering the body Administration of bolus or drip/infusion thrombolytic therapy or mechanical thrombectomy for the index PE event within 48 hours prior to enrollment Ventricular arrhythmias refractory to treatment at the time of enrollment Known to have heparin-induced thrombocytopenia (HIT) Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever or CDT System (for example, EKOS System) per local approved labeling Subject has previously completed or withdrawn from this study Patient unwilling or unable to conduct the follow up visits per protocol.